alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
## In the Court of Appeals Second Appellate District of Texas at Fort W orth

___________________________ No. 02

- 19

- 00290

- CR No

. 02

- 19

- 00291

- CR

___________________________

On Appeal from Criminal District Court No. 3 Tarrant County, Texas Trial Court No s . 1454393D, 1474527D

Before Kerr, Birdwell, and Bassel, JJ. Memorandum Opinio n by Justice Kerr 

### R

AFAE L 

### V ILLARD 

### , Appellant

V



### . T HE 

### S TATE OF 

### T EXAS2 MEMORANDUM OPINION Appellant Rafael Villard attempts to appeal from (1) the trial court ’ s j udgment adjudicating him guilty of assault of a family member by im ped ing the brea thing or

c irculation of the vict im, with a p revious family

- viole nce conviction , and (2) the trial

court ’ s judgment convicting him of assault of a family or household memb er , with a previous family

- violence con viction. See Te x. Penal C o de Ann

. § 22.01( b)( 2 )( A

) , (b

- 3)

. On February 10, 2017, the tria l court s entenced Villard to th ree years ’ confinement in each case with the sentences to run concurrently. Because Villard did not move for a

n ew trial in either case , h is noti ce of appeal in each ca se was due no later than March 13, 2017

. See Tex. R. App. P. 4.1(a), 26.2(a)(1)

. Over two years later, on July 25, 2019 , Villard filed a no tice of a ppeal attempting to appeal from both jud g ments
. On August 1 , 2019, w e noti fied Villard by letter o f our conc ern that w e lacked jur is dicti on over t hese a ppeals b ecaus e t he notice of a ppeal wa s untimely filed. See
T ex. R. App. P. 26.2(a)(1). We advised him that unless we received a response by
Au gust 12, 2019 , show ing grounds for continuing the a ppeal s , th e appeal s could be
di smissed for want of jur isdiction. See Tex. R . App

. P . 44.3

. We have re ceived no

r esponse.
Ou r appel late jurisdiction is triggered through a timely filed notice of appeal.
See Olivo v. State , 918 S.W.2d 519 , 522 (Tex. Crim. App. 1996). If a not i c e of appeal is not timely filed under rule 26.2, we do not have jurisdiction to address the merits of

t he appe al and may take no action other than to dismiss it

. See Slaton v. State ,3 981 S.W.2d 208, 210 (Te x. Crim. A pp. 1 998). B ecause Villard ’ s notice of a ppeal was untimely filed , we dismiss these appeals for want of jurisdiction. See Tex . R. App. P. 26.2(a ) (1) , 43.2(f ).

/s/ Elizabeth Kerr Elizabeth Kerr Justice
Do Not Publish Tex. R. App. P. 47.2(b)
Delivered : September 26, 2019
7/18/14 Page of



### INITIAL REVIEW EXPOSURE REPORT Summary Page

Chemical ID: P-14-0625 Re viewe r: Wong/BC

Endpoints- Assessed Table

Endpoints /Assessment Cycles 1 Releases

Assessed in

NCEM2? Reasons for not assessing releases

No X B

Test ing Required No

Hazard

Concern No

Release s Release

Below

Acute

Threshol d 5 Release

Below

Chronic

Threshold 5 Other

Ingestion

Surface water

Ground water ( landfill )

Consumer Use: DtD 2

Inhalation

Air : incineration ( stack )

Air : fugitive

Consumer Use: CEM 3

Dermal

Consumer Use: CEM

Eco

Surface water : ADR

conc and/or PDM 4

Consumer Use: DtD

1 Assessment cycles are endpoint concentrations and dose calculations within the NCEM2 model.

2 Down

- the

- Drain

3 Consumer Exposure Model

4 Probabilistic Dilution Model

5 The threshold values for assessing endpoints are 1 mg/day for acute doses and 1 mg/year for chronic doses.

EAB DROP: Release information for this compound does not meet criteria for preparation of an exposure assessment in the Exposure Assessment Branch = s (EAB) Initial Review Exposure Report (this report).
No. 11-5615.

#### William D. Williams, Petitioner v. Kenneth S. Tucker, Secretary, Florida Department of Corrections, et al.

565 U.S. 947, 132 S. Ct. 446,

181 L. Ed. 2d 265,

2011 U.S. LEXIS 7312.

October 11, 2011.

Petition for writ of certiorari to the United States Court of Appeals for the Eleventh Circuit denied.
No. 11-7322.

#### Johnny Draughn, Petitioner v. United States.

565 U.S. 1100, 132 S. Ct. 863,

181 L. Ed. 2d 563,

2011 U.S. LEXIS 8837.

December 12, 2011.

Petition for writ of certiorari to the United States Court of Appeals for the Fourth Circuit denied.
For more information: www.cdc.gov/COVID19

ACIP COVID-19 Vaccines Work Group

Dr. Beth Bell, Work Group Chair

December 19, 2020
 On December 18, 2020, the Food and Drug Administration (FDA) issued an 

Emergency Use Authorization (EUA) for use of the Moderna COVID-19 

vaccine for the prevention of Coronavirus Disease 2019 (COVID-19) for 

individuals 18 years of age and older

Update

2
Today’s agenda

3

 mRNA-1273 Development Program

Dr. Jacqueline M. Miller (Moderna) 

 GRADE: Moderna COVID-19 vaccine

Dr. Julia Gargano (CDC)

 Evidence to Recommendation Framework: Moderna COVID-19 vaccine

Dr. Sara Oliver (CDC)

 Public Comment

 Update on COVID-19 vaccines and Anaphylaxis

Dr. Tom Clark (CDC)

 Clinical Considerations for use of mRNA COVID-19 vaccines

Dr. Sarah Mbaeyi (CDC)

 Vote: 

Moderna COVID-19 vaccine
ACIP members

 Beth Bell (chair)

 Grace Lee

 Jose Romero

 Keipp Talbot

Ex-officio/government members

 FDA: Doran Fink, Rachel Zhang

 NIH: Chris Roberts

 IHS: Thomas Weiser, Jillian Doss-Walker

 DOD: Bryan Schumacher

 CMS: Jeff Kelman

 BARDA: Christine Oshansky

 HHS: David Kim

CDC Co-leads

 Kathleen Dooling

 Sara Oliver

Work group members

4

Liaisons

 AAFP: Jonathan Temte

 AAP: Sean O’Leary

 ACOG: Denise Jamieson (primary), 

Laura Riley (alternate)

 ACP: Jason Goldman

 AGS: Ken Schmader

 AIM: Rob Shechter (primary), Jane 

Zucker (alternate)

 AMA: Sandra Fryhofer

 ANA: Kendra McMillan (primary), 

Ruth Francis (alternate)

 APhA: Michael Hogue

 ASTHO: Marcus Plescia

 CSTE: Susan Lett

 IDSA: Jeff Duchin (primary), 

Carol Baker (alternate)

Liaisons, cont’d

 NACCHO: Matt Zahn (primary), 

Jeff Duchin (alternate)

 NACI: Matthew Tunis (primary), 

Linlu Zhao(alternate)

 NFID: Bill Schaffner (primary), 

Marla Dalton (alternate)

 NMA: Oliver Brooks

 SHEA: Marci Drees

Consultants

 Ed Belongia (safety)

 Matthew Daley (safety)

 Kathy Kinlaw (ethics)

 Dayna Matthew (health equity)

 Kathleen Neuzil (vaccinology)

 Stanley Perlman 

(microbiology/immunology)
 Doug Campos-Outcalt

 Mary Chamberland

 Thomas Clark

 Amanda Cohn

 Jean Cox-Ganser

 Katie Curran

 Jonathan Duffy

 Anthony Fiore

 Mark Freedman

 Sue Gerber

 Jack Gersten

 Susan Goldstein

 Sam Graitcer

 Lisa Grohskopf

 Julia Gargano

CDC participants

5

 Rita Helfand

 Terri Hyde

 Tara Jatlaoui

 Cynthia Jorgensen

 Erin Kennedy

 Ram Koppaka

 Jessica MacNeil

 Mona Marin

 Sarah Mbaeyi

 Nancy McClung

 Lucy McNamara

 Rebecca Morgan

 Titilope Oduyebo

 Christina Ottis

 Anita Patel

 Janell Routh

 Stephanie Schrag

 Tom Shimabukuro

 Natalie Thornburg

 Jennifer Verani

 Megan Wallace

 Cindy Weinbaum

 Yon Yu

 Jane Zucker
For more information, contact CDC

1-800-CDC-INFO (232-4636)

TTY: 1-888-232-6348 www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the 

official position of the Centers for Disease Control and Prevention.

Thank you!
Revised Exhibit A to Penn Virginia Corporation 2011



 Exhibit 10.1 
 EXHIBIT A 
 CASH BONUS PERCENTAGES 

Executive Officers 
  

											
	 	  	Percent of Base Salary	 
	 Officer
	  	Threshold	  	Target	 	  	Stretch	 
	 CEO
	  	0 – 50	  	 	100	  	  	 	200	  
	 COO
	  	0 – 50	  	 	100	  	  	 	200	  
	 CAO/GC
	  	0 – 40	  	 	80	  	  	 	160	  
	 CFO
	  	0 – 40	  	 	80	  	  	 	160	  
	 Sr. VP – Regional Manager
	  	0 – 40	  	 	80	  	  	 	160	  
	 VP – Regional Manager
	  	0 – 25	  	 	50	  	  	 	100	  

 Other Employees 
 Prior to March 1st of each Plan Year, the CEO shall approve and advise the Committee of the Target Cash Bonus Percentages for each Participant other than the Executive Officers. Such percentages shall be subject to
increase or decrease in the event of a promotion or demotion. 
 EQUITY INCENTIVE PERCENTAGES 

Executive Officers 
  

			
	 Officer
	  	Target Percent of Base Salary
	 CEO
	  	300 – 400
	 COO
	  	250 – 350
	 CAO/GC
	  	200 – 300
	 CFO
	  	200 – 300
	 Sr. VP – Regional Manager
	  	150 – 300
	 VP – Regional Manager
	  	150 – 300

 Other Employees 
 Prior to March 1st of each Plan Year, the CEO shall approve and advise the Committee of the Target Equity Incentive Percentages for each Participant other than the Executive Officers. Such percentages shall be subject to
increase or decrease in the event of a promotion or demotion.
Exhibit 23.3







VIA SEDAR / EDGAR



Ontario Securities Commission, as Principal Regulator

British Columbia Securities Commission

Alberta Securities Commission

United States Securities and Exchange Commission



Dear Sirs/Mesdames:



| | Re: | Sierra Metals Inc. (the “Company”)
| | --- | ----------------------------------

Annual Information Form
for the Company’s fiscal year ended December 31, 2017, incorporated by reference into the Company’s Prospectus Supplement
dated October 10, 2017 to the Short Form Base Shelf Prospectus dated June 29, 2017 (the “Prospectus Supplement”) and
the Annual Report incorporated by reference into the Company’s registration statement on Form F-10 (Registration No. 333-218076)
(the “Registration Statement”)

Consent of Qualified Person



Reference is made to the Annual Report
on Form 40-F for the fiscal year ended December 31, 2017 of the Company (the “Form 40-F”), filed with the United
States Securities and Exchange Commission pursuant to the Securities Exchange Act of 1934, as amended. Reference is also made to
the Annual Information Form of the Company for the year ended December 31, 2017 (the “AIF”), and its incorporation
by reference: (i) into the Prospectus Supplement, and (ii) as an exhibit to and incorporated by reference into the Form 40-F.



I hereby consent to the: (i) inclusion
of the summary section of the report entitled “NI 43-101 Technical Report on Resources and Reserves, Yauricocha Mine,
Yauyos Province, Peru” dated effective July 31, 2017 (the “Yauricocha Technical Report”) in the AIF
and any amendments thereto, and the incorporation of this report in the AIF, (ii) incorporation of the AIF in the Form 40-F and
any amendments thereto, and in the Company's Registration Statement, including the prospectus contained therein, as amended or
supplemented, (iii) incorporation by reference of the AIF and any amendments thereto, into the Prospectus Supplement and (iv) being
named in, and the use of the Yauricocha Technical Report or portions thereof prepared, reviewed and/or approved by me, in the AIF
and Form 40-F.



I also hereby confirm that I have read
the AIF and have no reason to believe that there are any misrepresentations in the information contained therein derived from the
Yauricocha Technical Report or within my knowledge as a result of the services I performed in connection with the Yauricocha Technical
Report.



[Signature page follows]



1







Dated: March 22, 2018



|/s/ Shannon L. Rheaume                                      | 
|----------------------------------------------------------- | 
|Shannon L. Rheaume, BASc Mining andMineral Processing, PEng | 





2
Exhibit 12

THE TITAN CORPORATION        COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES        (DOLLAR AMOUNTS IN THOUSANDS)

|                                                             |  | YEAR ENDED DECEMBER 31,
|------------------------------------------------------------ |  | -----------------------
|
|Earnings                                                     |  |                        
|Income (loss) from continuing operations before income taxes |  | $                      
|Fixed charges                                                |  |                        
|                                                             |  |                        
|Earnings                                                     |  | $                      
|                                                             |  |                        
|Fixed charges:                                               |  |                        
|Interest expense                                             |  | $                      
|Interest factor included in rents                            |  |                        
|                                                             |  |                        
|Fixed charges                                                |  | $                      
|                                                             |  |                        
|Ratio of earnings to fixed charges                           |  |                        
|Deficiency                                                   |  | $                      

---



QuickLinks
No. 11-6659.

#### Rodolfo Sanabria Sanchez, Petitioner v. United States.

565 U.S. 993, 132 S. Ct. 539,

181 L. Ed. 2d 377,

2011 U.S. LEXIS 7654.

October 31, 2011.

Petition for writ of certiorari to the United States Court of Appeals for the Tenth Circuit denied.

Same case below, 431 Fed. Appx. 664.
[Federal Register Volume 63, Number 149 (Tuesday, August 4, 1998)]
[Proposed Rules]
[Page 41538]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 98-20748]


=======================================================================
-----------------------------------------------------------------------

FEDERAL COMMUNICATIONS COMMISSION

47 CFR Parts 1, 43 and 63

[IB Docket No. 98-118, FCC 98-149]


Biennial Review of International Common Carrier Regulations; 
Correction

AGENCY: Federal Communications Commission.

ACTION: Proposed rule; correction.

-----------------------------------------------------------------------

SUMMARY: This document corrects the dates that comments and reply 
comments are to be filed on a proposed rule published in the Federal 
Register on July 24, 1998, regarding Biennial Review of International 
Common Carrier Regulations.

FOR FURTHER INFORMATION CONTACT: Douglas Klein, Attorney-Advisor, 
Policy and Facilities Branch, Telecommunications Division, 
International Bureau, (202) 418-1470. Correction: In proposed rule FR 
Doc. 98-43, beginning on page 39793 in the Federal Register issue of 
July 24, 1998, the DATES section is corrected to read:

DATES: Comments are due on or before August 13, 1998; and reply 
comments are due on or before August 28. Written comments by the public 
on the proposed information collections are due September 22, 1998.

    Dated: July 29, 1998.

Federal Communications Commission.
Magalie Roman Salas,
Secretary.
[FR Doc. 98-20748 Filed 8-3-98; 8:45 am]
BILLING CODE 6712-01-M
Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
							Search

		Submit


Lymphocytic Choriomeningitis (LCM)


Facebook
        Twitter
        LinkedIn
        Syndicate





Transmission																									Related Pages
												LCMV infections can occur after exposure to fresh urine, droppings, saliva, or nesting materials from infected rodents. Transmission may also occur when these materials are directly introduced into broken skin, the nose, the eyes, or the mouth, or presumably, via the bite of an infected rodent. Person-to-person transmission has not been reported, with the exception of vertical transmission from infected mother to fetus, and rarely, through organ transplantation.Related LinksRodentsArenaviruses

			
							
								Page last reviewed:  May 6, 2014						Content source:  	Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Division of High-Consequence Pathogens and Pathology (DHCPP), Viral Special Pathogens Branch (VSPB) Lymphocytic Choriomeningitis (LCM)
Transmission
Signs & Symptoms
Risk of Exposure
Diagnosis
Treatment
Prevention
Resources About VSPB (Viral Special Pathogens Branch)


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue
≥95% (3 awardees)

75% - 94% (15 awardees)

50% - 74% (21 awardees)

25% - 49% (9 awardees)

<25% (5 awardees)

No IIS (1 awardee)

No data (2 awardees)

Percentage of adults aged ≥19 years participating in an immunization 

information system -- United States, five cities§, and D.C., 2018

National Participation: 56% (excluding Territories)

Source: CY2018 IISAR

§ Chicago, IL; Houston, TX; New York City, NY; Philadelphia, PA; San Antonio, TX.
No. 11-6726.

#### Eldridge Simpson, Petitioner v. United States.

565 U.S. 994, 132 S. Ct. 541,

181 L. Ed. 2d 379,

2011 U.S. LEXIS 7609.

October 31, 2011.

Petition for writ of certiorari to the United States Court of Appeals for the Fifth Circuit denied.

Same case below, 645 F.3d 300.
No. 11-5683.

#### Edward Dorsey, Sr., Petitioner v. United States. Corey A. Hill, Petitioner v. United States.

No. 11-5721.

565 U.S. 1057, 132 S. Ct. 759,

181 L. Ed. 2d 480,

2011 U.S. LEXIS 8649.

November 28, 2011.

Motions of petitioners for leave to proceed in forma pauperis granted. Petitions for writs of certiorari to the United States Court of Appeals for the Seventh Circuit granted. The cases are consolidated and a total of one hour is allotted for oral argument.

Same cases below, 635 F.3d 336 (No. 11-5683); 417 Fed. Appx. 560 (No. 11-5721).
EXHIBIT 32

CERTIFICATIONS

(Pursuant to 18 U.S.C. Section 1350)

The undersigned hereby certifies that, to his knowledge (i) the Form 10-Q filed by ECB Bancorp, Inc. (the Issuer) for the
quarter ended June 30, 2006, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and (ii) the information contained in that Report fairly presents, in all material respects,
the financial condition and results of operations of the Issuer on the dates and for the period presented therein.



|                      |  |                                                  
|--------------------- |  | -------------------------------------------------
|Date: August 14, 2006 |  | /s/ Arthur H. Keeney                             
|                      |  | Arthur H. Keeney III                             
|                      |  | President and Chief Executive Officer            
|                      | 
|                      |  | /s/ Gary M. Adams                                
|Date: August 14, 2006 |  | Gary M. Adams                                    
|                      |  | Senior Vice President and Chief Financial Officer
ex10-harding.htm



Exhibit 10.47


 


Fifth Amendment


To


Change of Control and Severance Benefits Agreement







This Fifth Amendment (the “Fifth Amendment”) to Change of Control and Severance Benefits Agreement is made this 31st day of January 2012, by and between ImageWare Systems, Inc., a Delaware corporation (the “Company”), on the one hand, and David Harding, Vice President of Engineering and Chief Technical Officer, on the other hand (the “Executive”).  


                    


WHEREAS, the Company and the Executive entered into a Change of Control and Severance Benefits Agreement dated as of May 21, 2007 which was then subsequently amended on September 27, 2008, April 6, 2009, December 10, 2009 and again on March 10, 2011   (the “Severance Agreement”); and







WHEREAS, the Executive continues to perform valuable services for the Company and the Company desires to assure itself of the continuing services of Executive; and







WHEREAS, in consideration of the foregoing and in order to amend the terms of the Agreement and to provide for the continued services of the Executive in accordance with the present intent of the Company and the Executive.







NOW THEREFORE, in consideration of the foregoing and for other good and valuable consideration, receipt of which is hereby acknowledged, and in further consideration of the mutual covenants contained in the Severance Agreement, the parties do hereby agree that the Severance Agreement is hereby amended as follows:







Section “2. Term of Agreement” strike the language “continue until December 31, 2011” and replace it with “continue until June 30, 2012”.




 






	
/s/ Wayne Wetherell


ImageWare Systems, Inc.

	
/s/ David Harding


David Harding
EX-10.27



 Exhibit 10.27 
 November 16, 2004 
 Richard Gillette 
 [                    ] 
 Elmhurst, IL 60126 
 Re: Offer of Employment 

Dear Rich: 
 We very much
enjoyed our recent discussions with you and I am happy to confirm our offer of employment. 
 We would like you to join our team
as a Vice President. Your starting salary will be $190,000 per year paid semi-monthly. You will be eligible for health benefits immediately upon your Start Date. You will also be eligible for a discretionary annual bonus of up to $60,000 based upon
your performance and that of the Company. 
 Additionally, you will be granted Options to acquire 90,000(1) shares of Accretive
Health stock pursuant to the terms and conditions established for the Accretive Health Employee Stock Option Plan. Among the terms and conditions for these Options will be a vesting period to be established by the Accretive Health Board of
Directors. 
 We will work with you to determine a mutually agreeable start date. If you have any questions please do not
hesitate to give me a call. I can be reached at the following numbers: [            ] (work), [            ] (mobile),
[            ] (home). 
 Rich, I truly believe that we are building
the best team in the industry and that you will enjoy the opportunity to work with your peers. I look forward to hearing from you soon, and also working with you. 

 

	
	Best Regards,
	
	 /s/ Greg Kazarian

	Greg Kazarian
	General Counsel


  

	
	 Agreed and Accepted

	
	 /s/ Richard Gillette

	 Richard Gillette


  

	(1)	The Company effected a 3.92-for-one stock split on May 3, 2010, which is not reflected in the number above.